Table 1 Patient and tumor characteristics in correlation to TGM2 expression.

From: Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target

Characteristic

Total cohort

TGM2 expression

P-value

(n = 279)

Weak (n = 123)

Moderate (n = 105)

Strong (n = 51)

Mean age ± SD (years)

67.9 (12.3)

66.4 (12.9)

70.5 (11.6)

65.9 (11.2)

0.023

Sex

    

0.911

 Male

156 (55.9)

67 (54.5)

60 (57.1)

29 (56.9)

 Female

123 (44.1)

56 (45.5)

45 (42.9)

22 (43.1)

Charlson comorbidity index

    

0.101

 <3

100 (35.8)

46 (37.4)

39 (37.1)

15 (29.4)

 3–4

69 (24.7)

38 (30.9)

20 (19.0)

11 (21.6)

 >4

110 (39.4)

39 (31.7)

46 (43.8)

25 (49.0)

Tumor location

    

0.229

 Ascending colon

134 (48.0)

66 (53.7)

48 (45.7)

20 (39.2)

 Descending colon

37 (13.3)

16 (13.0)

11 (10.5)

10 (19.6)

 Sigmoid

108 (38.7)

41 (33.3)

46 (43.8)

21 (7.5)

Tumor differentiation

    

0.183

 Well to moderate

238 (86.9)

105 (86.8)

94 (90.4)

39 (79.6)

 Poor

36 (13.1)

16 (13.2)

10 (9.6)

10 (20.4)

Tumor depth

    

0.157

 T1

13 (4.7)

7 (5.7)

5 (4.8)

1 (2.0)

 T2

45 (16.1)

25 (20.3)

15 (14.3)

5 (9.8)

 T3

169 (60.6)

75 (61.0)

64 (61.0)

30 (58.8)

 T4

52 (18.6)

16 (13.0)

21 (20.0)

15 (29.4)

Lymph node status

    

<0.001

 N0

154 (55.6)

84 (68.9)

52 (50.0)

18 (35.3)

 N1

60 (21.7)

17 (13.9)

31 (29.8)

12 (23.5)

 N2

63 (22.7)

21 (17.2)

21 (20.2)

21 (41.2)

Distant metastasis

    

< 0.001

 M0

227 (82.2)

111 (91.7)

85 (81.0)

31 (62.0)

 M1

49 (17.8)

10 (8.3)

20 (19.0)

19 (38.0)

Lymphatic invasion

    

0.017

 L0

154 (57.7)

74 (64.9)

60 (57.7)

20 (40.8)

 L1

113 (42.3)

40 (35.1)

44 (42.3)

29 (59.2)

Venous invasion

    

0.030

 V0

238 (88.8)

103 (90.4)

95 (92.2)

40 (78.4)

 V1

30 (11.2)

11 (9.6)

8 (7.8)

11 (21.6)

Perineural invasion

    

0.078

 Pn0

211 (87.9)

96 (92.3)

81 (87.1)

34 (79.1)

 Pn1

29 (12.1)

8 (7.7)

12 (12.9)

9 (20.9)

UICC stage

    

<0.001

 I

45 (16.1)

29 (23.6)

13 (12.4)

3 (5.9)

 II

101 (36.2)

54 (43.9)

34 (32.4)

13 (25.5)

 III

83 (29.7)

30 (24.4)

38 (36.2)

15 (29.4)

 IV

50 (17.9)

10 (8.1)

20 (19.0)

20 (39.2)

Tumor relapse/progress

    

 < 0.001

 No

175 (69.2)

100 (39.3)

61 (64.9)

14 (29.8)

 Yes

78 (30.8)

12 (10.7)

33 (35.1)

33 (70.2)

Mean CEA

    

0.094

 Mean ± SD (ng/ml)

438 (4998)

9 (22)

218 (1752)

2028 (11779)

Adjuvant therapy

87 (32.7)

27 (23.1)

36 (35.3)

24 (51.1)

0.002

p53 status

    

0.009

 Wildtype

133 (51.2)

70 (61.9)

44 (43.6)

19 (41.3)

 Mutant

127 (48.8)

43 (38.1)

57 (56.4)

27 (58.7)

Kras status

    

0.041

 Wildtype

29 (31.2)

7 (17.5)

12 (38.7)

10 (45.5)

 Mutant

64 (68.8)

33 (82.5)

19 (61.3)

12 (54.5)

  1. NOTE: Values are No. (%) unless otherwise indicated. For analysis of categorical variables Chi-square test was used. Fishers exact test was used, if appropriate. For continuous variables one-way ANOVA analysis with Bonferroni correction was performed. UICC International Union Against Cancer, CEA Carcinoembryonic antigen, TGM2 Transglutaminase 2.
  2. Bold values indicates statistical significant P values (P < 0.05).
Back to article page